HONG KONG – Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), and collaborators from the Zhongshan Ophthalmic Centre of Sun Yat-sen University, Guangzhou, have developed a light-activatable prodrug nanomedicine for age-related macular degeneration (AMD) therapy. Through the intravenous injection of the nanomedicine and application...
Latest News
Hong Kong – A research team led by Professor Anskar Leung Yu-hung, from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has identified PLK4 as a novel therapeutic target for acute myeloid leukaemia (AML) carrying the TP53 mutation. AML is...
The fourth edition of the successful Doha–Heidelberg research conference on Rare Diseases was recently hosted by Hamad Medical Corporation (HMC) and Heidelberg University Hospital at the Itqan Simulation and Clinical Innovation Centre in Doha. The specialised educational conference discussed updates on the diagnosis and management of rare diseases with an...
Stanford, California – A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others who are likely to experience a disease recurrence — potentially letting some patients...
Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke, according to a new study published June 17 online in the Journal of the National Cancer Institute. The study was undertaken because information on clinically verified stroke and transient ischemic attack (TIA), or a “mini...
Berlin – Hodgkin’s lymphoma is one of the most common types of lymphoma in young adults. It is characterized by the presence of enlarged B lymphocytes, which are unusual in that they bear on their surface the identifying markers of many other immune cells – such as those found on...
St. Paul MN – Some of the things seven-year-old Holli loves about school are getting candy on her birthday, math (she could do math all day!), and playing on the swings during recess. Her specialized paraprofessional, Mr. Tyler, joins her in swinging and in hallway banter as they navigate Holli’s...
Bedford, Mass. — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments. “We entered 2023 with strong momentum across our gene editing and gene therapy clinical trials for PKU and Hunter syndrome,...
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET.
NEW YORK, NY and VIENNA — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700,...